Prevention strategies against the human papillomavirus: The effectiveness of vaccination

This publication has 16 references indexed in Scilit:

• Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials
  The Lancet, 2007
• Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases
  New England Journal of Medicine, 2007
• Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions
  New England Journal of Medicine, 2007
• Cost-effectiveness analyses of human papillomavirus vaccination
  The Lancet Infectious Diseases, 2007
• High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up
  British Journal of Cancer, 2006
• Chapter 12: Prophylactic HPV vaccines: Underlying mechanisms
  Vaccine, 2006
• Condom Use and the Risk of Genital Human Papillomavirus Infection in Young Women
  New England Journal of Medicine, 2006
• Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
  The Lancet, 2006
• Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine
  JNCI Journal of the National Cancer Institute, 2004
• Cervical cancer and sexual lifestyle: a systematic review of health education interventions targeted at women.
  Health Education Research, 2000